9 studies found for:    TBR-652
Show Display Options
Rank Status Study
1 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
2 Recruiting Effect of Cenicriviroc on HIV Neurocognitive Impairment
Conditions: AIDS Dementia Complex;   HIV-1-Associated Cognitive Motor Complex;   Human Immunodeficiency Virus
Intervention: Drug: cenicriviroc
3 Completed Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
Condition: HIV-infection/AIDS
Interventions: Drug: Cenicriviroc;   Drug: Dolutegravir;   Drug: Midazolam
4 Completed Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment
Condition: Liver Insufficiency
Interventions: Drug: Cenicriviroc in mild liver impaired;   Drug: Cenicriviroc in moderate liver impaired
5 Recruiting Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: Cenicriviroc;   Drug: Placebo
6 Completed Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg;   Drug: Cenicriviroc 200 mg + Truvada;   Drug: Sustiva + Truvada
7 Active, not recruiting Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
Condition: Healthy
Interventions: Drug: Cenicriviroc;   Drug: Pioglitazone
8 Terminated Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
Condition: HIV Infection
9 Enrolling by invitation Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes and Suspected NAFLD (ORION)
Conditions: Prediabetic State;   Non-alcoholic Fatty Liver Disease
Interventions: Drug: Cenicriviroc 150 mg;   Drug: Matching placebo

Indicates status has not been verified in more than two years